Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281
Alfredo Carrato, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, describes interesting trials discussed at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. An interesting trial presented this year investigated FOLFOXIRI plus panitumumab (NCT01358812). It found a high response rate in patients with RAS wild-type metastatic colorectal cancer. Another interesting trial investigated whether to add an EGFR inhibitor after treatment with bevacizumab in RAS wild-type colorectal cancer showed that bevacizumab conferred an improvement in progression free survival.